| Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia BD Santomasso, JH Park, D Salloum, I Riviere, J Flynn, E Mead, E Halton, ... Cancer discovery 8 (8), 958-971, 2018 | 720 | 2018 |
| Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology, JCO. 20.00290, 2020 | 346* | 2020 |
| Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma K Wudhikarn, ML Palomba, M Pennisi, M Garcia-Recio, JR Flynn, ... Blood cancer journal 10 (8), 79, 2020 | 170 | 2020 |
| A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer AY Ho, CA Barker, BB Arnold, SN Powell, ZI Hu, A Gucalp, ... Cancer 126 (4), 850-860, 2020 | 150 | 2020 |
| Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations JM Mota, E Barnett, JT Nauseef, B Nguyen, KH Stopsack, A Wibmer, ... JCO Precision Oncology 4, 355-366, 2020 | 113 | 2020 |
| High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy EK Bartlett, JR Flynn, KS Panageas, RA Ferraro, JM Sta. Cruz, MA Postow, ... Cancer 126 (1), 76-85, 2020 | 108 | 2020 |
| DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality K Wudhikarn, M Pennisi, M Garcia-Recio, JR Flynn, A Afuye, ... Blood Advances 4 (13), 3024-3033, 2020 | 98 | 2020 |
| Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies D Sermer, C Batlevi, ML Palomba, G Shah, RJ Lin, MA Perales, M Scordo, ... Blood Advances 4 (19), 4669-4678, 2020 | 88 | 2020 |
| Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells M Pennisi, M Sanchez-Escamilla, JR Flynn, R Shouval, A Alarcon Tomas, ... Blood Advances 5 (17), 3397-3406, 2021 | 80 | 2021 |
| Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy R Shouval, A Alarcon Tomas, JA Fein, JR Flynn, E Markovits, S Mayer, ... Journal of clinical oncology 40 (4), 369-381, 2022 | 77 | 2022 |
| A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response AA Hakimi, K Attalla, RG DiNatale, I Ostrovnaya, J Flynn, KA Blum, Y Ged, ... Nature Communications 11 (1), 1-11, 2020 | 63* | 2020 |
| Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer FY Anthony, JR Flynn, CS Moskowitz, JM Scott, KC Oeffinger, CT Dang, ... JAMA cardiology 5 (3), 309-317, 2020 | 59 | 2020 |
| Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy K Wudhikarn, JR Flynn, I Rivière, M Gönen, X Wang, B Senechal, ... Blood, The Journal of the American Society of Hematology 138 (7), 531-543, 2021 | 56 | 2021 |
| Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions NJ Choudhury, AJ Schoenfeld, J Flynn, CJ Falcon, H Rizvi, CM Rudin, ... Clinical Cancer Research 27 (10), 2920-2927, 2021 | 52 | 2021 |
| MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors A Bhatia, M Birger, H Veeraraghavan, H Um, F Tixier, AS McKenney, ... Neuro-oncology 21 (12), 1578-1586, 2019 | 49 | 2019 |
| Immune Checkpoint Inhibitor–Associated Diabetes: A Single-Institution Experience DJ Byun, R Braunstein, J Flynn, J Zheng, RA Lefkowitz, S Kanbour, ... Diabetes Care 43 (12), 3106-3109, 2020 | 37 | 2020 |
| Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia K Perica, J Flynn, KJ Curran, I Rivere, X Wang, B Senechal, E Halton, ... Leukemia 35 (11), 3268-3271, 2021 | 36* | 2021 |
| Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers NJ Choudhury, A Marra, JSY Sui, J Flynn, SR Yang, CJ Falcon, ... Journal of Thoracic Oncology 18 (4), 463-475, 2023 | 34 | 2023 |
| Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation … A Lin, J Flynn, L DeRespiris, B Figgins, M Griffin, C Lau, A Proli, ... Transplantation and Cellular Therapy 27 (1), 85. e1-85. e6, 2021 | 34 | 2021 |
| Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases I Kurilova, RGH Beets-Tan, J Flynn, M Gönen, G Ulaner, EN Petre, ... Clinical colorectal cancer 18 (1), 8-18, 2019 | 33 | 2019 |
